Authors
Javier Cañueto, Vishal A Patel, David R Carr, Anokhi Jambusaria-Pahlajani, Aaron Mangold, Fabio Muradás Girardi, Emily S Ruiz, Marlies Wakkee, Ashley Wysong
Published in
American journal of clinical dermatology. Nov 10, 2026. Epub Nov 10, 2026.
Abstract
Cutaneous squamous cell carcinoma (cSCC) is a common skin malignancy whose incidence has risen sharply over the past decade. During this period, significant progress in cSCC management has also occurred, which has evolved from an almost purely surgically based approach to a more complex multidisciplinary management. Prognostic assessment now integrates clinicopathologic factors and has enabled more precise and individualized risk models, and gene expression profiling has also emerged as potentially useful in specific clinical scenarios. Imaging has become increasingly utilized in clinical practice given its increasingly recognized impact on management decisions. Evidence supports complete surgical margin assessment as the standard for high-risk (T2b/T3-BWH) cSCC and has helped refine optimal selection for the use of adjuvant radiotherapy, but most evidence is based on retrospective cohort studies. Immune checkpoint inhibitors have transformed systemic treatment: cemiplimab, pembrolizumab, and cosibelimab are approved for locally advanced or metastatic disease, and cemiplimab is also approved in the adjuvant setting. Neoadjuvant immunotherapy can also produce deep responses, raising the possibility of treatment de-escalation. Secondary prevention is also growing, particularly among high-risk populations, with oral nicotinamide, acitretin, and topical field-directed therapies showing potential utility, but sometimes lacking strong evidence. Collectively, these developments are redefining cSCC management across the disease continuum, enabling diagnostic, therapeutic, surveillance, and preventive strategies to be increasingly tailored to individual risk and clinical context, but there is still a need for generating new data and stronger evidence at some points.
PMID:
43007641
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0